Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993
Tolrestat for Mild Diabetic Neuropathy, A 52-Week Randomized, Placebo-Controlled Trial
Ann Int Med 118:7-11, Guigliano,D.,et al, 1993
When Selegiline is Prescribed, Stelazine May be Mistakenly Dispensed
Neurol 43:228, Zweig,R.M.&Davis,P.H., 1993
Dopaminergic Treatment of Restless Legs and Rebound Phenomenon
Neurol 43:455, Guilleminault,C.,et al, 1993
A Novel Antineuronal Antibody in Stiff-Man Syndrome
Neurol 43:114-120, Darnell,R.B.,et al, 1993
Levodopa, Melanoma, and Parkinson's Disease
Neurol 43:674-677, Weiner,W.J.,et al, 1993
Comparison of Striatal 18F-dopa Uptake in Adult-Onset Dystonia-Parkinsonism, Parkinson's & Dopa-Responsive Dystonia
Neurol 43:1563-1568, Turjanski,N.,et al, 1993
Clinical Experience with Controlled-Release Carbidopa/Levodopa in Parkinson's Disease
Neurol 43:677-681, Pahwa,R.,et al, 1993
Levodopa Improves Spatial Contrast Sensitivity in Parkinson's Disease
Arch Neurol 50:721-724, Hutton,J.T.,et al, 1993
The Spectrum of Levodopa-Related Fluctuations in Parkinson's Disease
Neurol 43:1459-1464, Riley,D.E.&Lang,A.E., 1993
Blood Levodopa Levels and Unified Parkinson's Disease Rating Scale Function:With and Without Exercise
Neurol 43:1040-1042, Goetz,C.G.,et al, 1993
The Sorbinil Retinopathy Trial:Neuropathy Results
Sorbinil Retinopathy Trial Research Group, Neurol 43:1141-11491993., , 1993
Acetazolamide-Induced Nephrolithiasis:Implications for Treatment of Neuromuscular Disorders
Neurol 43:1105-1106, Tawil,R.,et al, 1993
One-Year Reduction and Longitudinal Analysis of Carotid Intima-Media Thickness Associated with Colestipol/Niacin Therapy
Stroke 24:1779-1783, Mack,W.J.,et al, 1993
The Neurologic Syndrome of Vitamin E Deficiency:A Significant Cause of Ataxia
Neurol 43:2167-2169, Kayden,H.J., 1993
Evidence for a Dopaminergic Deficit in Sporadic Amyoptrophic Lateral Sclerosis on Positron Emission Scanning
Lancet 324:1016-1018, Takahashi,H.,et al, 1993
Idiopathic Intracranial Hypertension:Report of Seven Cases
Am J Med 93:391-395, Jain,N.&Rosner,F., 1992
The Effect of Exercise on Levodopa Absorption
Neurol 42:2042-2045, Carter,J.H.,et al, 1992
Apomorphine Test for Dopaminergic Response in Pts with Previously Untreated Parkinson's
Arch Neurol 49:1131-1134, Gasser,T.,et al, 1992
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA 268:2523-2529, 25641992., Farlow,M.,et al, 1992
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Dissease
NEJM 327:1253-1259, 13061992., Davis,K.L.,et al, 1992
The Antiparkinson Efficacy of Deprenyl Derives from Transient Improvement that is Likely to be Symptomatic
Ann Neurol 32:795-798, Schulzer,M.,et al, 1992
Selegiline as Initial Treatment of De Novo Parkinsonian Patients
Neurol 42:339-343, Myllyla,V.V.,et al, 1992
Periodic Triphasic Waves in Levodopa-Induced Encephalopathy
Neurol 42:444-446, Neufeld,M.Y., 1992
123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism
Neurol 42:556-561, Schwarz,J.,et al, 1992
Antibodies to Oxidised LDL in Atherosclerosis
Editorial, Lancet 339:899-9001992., , 1992
Serum Concentrations of Vitamins A and E and Early Outcome after Ischaemic Stroke
Lancet 339:1562-1565, DeKeyser,J.,et al, 1992
The Effect of Acetazolamide on Essential Tremor:An Open-Label Trial
Neurol 42:1394-1395, Busenbark,K.,et al, 1992
Treatment of Nocturnal Leg Cramps, A Crossover Trial of Quinine vs Vitamin E
Arch Int Med 152:1877-1880, Connolly,P.S.,et al, 1992
Nerve Agents:A Review
Neurol 42:946-950, Gunderson,C.H.,et al, 1992
Levodopa-Nonresponsive Lewy Body Parkinsonism:Clinicopathologic Study of Two Cases
Neurol 42:1323-1327, Mark,M.H.,et al, 1992
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Stereotactic Ventrolateralis Thalamotomy for Refractory Tremor in Post-Levodopa Era Parkinson's Dis
J Neurosurg 75:723-730, Fox,M.W.,et al, 1991
Neuroleptic Malignant Synd in Parkinson's after Withdrawal or Alteration of Dopaminergic Therapy
Arch Int Med 151:794-796, Keyser,D.L.&Rodnitzky,R.L., 1991
Controlled-Release Delivery of L-Dopa Associated with Nonfatal Hyperthermia, Rigidity, and Autonomic Dysfunction
Neurol 41:942-943, Cunningham,M.A.,et al, 1991
Young-Onset Parkinson's Disease:A Clinical Review
Neurol 41:168-173, Golbe,L.I., 1991
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Aseptic Meningitis Following Cardiac Transplantation:Clinical Characteristics & Relationship to Immunosuppressive Regimen
Neurol 41:249-252, Adair,J.C.,et al, 1991
Treatment of Guillain-Barre Syndrome with Anti-T Cell Monoclonal Antibodies
JNNP 54:51-54, Feasby,T.E., 1991
Management of Injuries Due to Chemical Weapons
BMJ 302:129-130, Murray,V.S.G.&Volans,G.N., 1991
Dopa-Responsive Dystonia:Long-Term Treatment Response and Prognosis
Neurol 41:174-181, Nygaard,T.G.,et al, 1991
Acetazolamide-Responsive Vestibulocerebellar Syndrome:Clinical & Oculographic Features
Neurol 41:429-433, Baloh,R.W.&Winder,A., 1991
Presynaptic Parkinsonism in Olivopontocerebellar Atrophy:Clinical, pathological, and Neurochemical Evidence
Ann Neurol 30:425-428, Pascual,J.,et al, 1991
Tacrine in Alzheimer's Disease
Lancet 337:989-992, Eagger,S.A.,et al, 1991
Severe Adverse Interaction Between Pethidine and Selegiline
Lancet 337:246, Zornberg,G.L.,et al, 1991
Gemfibrozil-Induced Myopathy
Arch Int Med 151:1873-1874, Magarian,G.J.,et al, 1991
Cholesterol-Lowering Agent Myopathy (CLAM)
Neurol 41:1159-1160, London,S.F.,et al, 1991
Pyridostigmine Used as a Nerve Agent Pretreatment Under Wartime Conditions
JAMA 266:693-695, Keeler,J.R.,et al, 1991
Dopa-responsive Dystonia:[18F]Dopa Positron Emission Tomography
Ann Neurol 30:24-30, Sawle,G.V.,et al, 1991
DATATOP and Clinical Neuromythology IX
Special Correspondence, Neurol 41:771-7771991., , 1991